|
|
Vaccine Detail
|
Recombinant Modified Vaccinia Ankara-5T4 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Modified Vaccinia Ankara-5T4 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007016
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TPBG
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Modified Vaccinia Ankara is used to transfect 5T4 cDNA into epithelial target cells (Tykodi and Thompson, 2008).
- Description: This is for Breast Cancer (NCT00227474). A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly (NCIT_C49087).
|
| Host Response |
|
|
| References |
NCIT_C49087: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49087]
NCT00227474: [https://clinicaltrials.gov/show/NCT00227474/]
Tykodi and Thompson, 2008: Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert opinion on biological therapy. 2008; 8(12); 1947-1953. [PubMed: 18990081].
|
|
